Work

Dalbavancin

Year: 2026

Type: article

Abstract: It is also used to treat Staphylococcus aureus bacteremia once identified on blood culture and S. aureus bone or joint infections.[2][1] In a randomized trial involving 200 patients with complicated S. aureus bacteremia, 2 doses of intravenous dalbavancin were noninferior to 4 to 8 weeks of other

Source: Canadian Medical Association Journal

DOI: 10.1503/cmaj.251756

Authors: Isabella R. Stevenson, Anthony D. Bai, Kiarah Shchepanik

Institutions: Queen's University, Kingston Health Sciences Centre

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,553